Key Drivers
- Margin Compression
- Rising Leverage
- Weak Cash Flow
AIAI Summary
HROW is no longer just a distressed specialty pharma name—the core products are now driving credible commercial growth—but the stock remains a high-risk turnaround until VEVYE/IHEEZO momentum translates into consistent free cash flow and meaningful deleveraging, because reimbursement volatility and rising leverage can still erase the upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Compression
- •Rising Leverage
- •Weak Cash Flow
HROW remains liquid and gross-margin positive, but sharply weaker recent results, rising leverage, and negative earnings make the stock look financially stretched and high risk.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Range consolidation
- •Extended rally
Over the last month, HROW is still trending higher with strong momentum and higher lows, but it looks stretched near $43 resistance and needs to hold $41.15-$41.50 for continuation.
Fast rally from $33.10 to $43.00 suggests short-term extension risk
Sentiment & News
Key News Insights:
- •VERKAZIA relaunch
- •Retina portfolio boost
- •U.S. commercialization
Harrow is expanding its ophthalmology franchise by relaunching VERKAZIA and launching BYOOVIZ in the U.S., strengthening its presence in pediatric and retina treatments.
This should support Harrow's growth narrative by broadening access to approved eye therapies and expanding its commercial footprint in ophthalmology
Similar Companies in Healthcare
Other companies in the same sector with AI ratings